Bioequivalence and Bioavailability Forum 20:48 CEST

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log in |  Register |  Search

What's the current situation regarding chiral assays? [Bioanalytics]

posted by ElMaestro - Denmark, 2017-12-16 12:31  - Posting: # 18064
Views: 1,222

Hi all,

what is the current regulatory sentiment towards the need for chiral assays?

My impression is, given the EU guideline wording in 4.1.5 and the current practice that I have seen that regulators are not really enforcing the guideline the way it is written but occasionally they just happen to be.
I cannot see a pattern in the practice. If someone asks me when a chiral assay is truly necessary (guideline wording apart) then I will have to draw a blank.

Anyone out there able to describe how the guideline wording translates into assessor practice in plain words?

Many thanks and have a good day.

if (3) 4

Best regards,

"(...) targeted cancer therapies will benefit fewer than 2 percent of the cancer patients they’re aimed at. That reality is often lost on consumers, who are being fed a steady diet of winning anecdotes about miracle cures." New York Times (ed.), June 9, 2018.

Complete thread:

 Mix view
Bioequivalence and Bioavailability Forum |  Admin contact
18,783 posts in 4,003 threads, 1,258 registered users;
online 18 (1 registered, 17 guests [including 12 identified bots]).

To propose that poor design can be corrected by subtle analysis techniques
is contrary to good scientific thinking.    Stuart J. Pocock

BEBAC Ing. Helmut Schütz